Immix Biopharma
ImmixBio was founded in 2012 by a visionary physician/scientist, a world-renown pharmacology expert, a seasoned biotechnology patent attorney and an impact-driven founding family office. We are developing an entirely new class of Tissue-Specific Therapeutics, or TSTx, which we believe will replace first-line therapies across a multitude of cancer indications.Content by Immix Biopharma
| 1 min read
A new kid on the block flips the script using a systems biology-inspired tissue-specific approach against metastatic cancer that normalizes the tumor microenvironment.
Page 1 of 1 - 1 Total Items
